"Vybran\u00E9 ot\u00E1zky onkologie XV." . . . . "RIV/61989592:15110/11:10225271!RIV12-MZ0-15110___" . "Lok\u00E1ln\u00ED terapi\u00ED karcinomu prostaty rozum\u00EDme radik\u00E1ln\u00ED opera\u010Dn\u00ED \u010Di radia\u010Dn\u00ED l\u00E9\u010Dbu. Sledov\u00E1n\u00ED pacient\u016F po ukon\u010Den\u00E9 l\u00E9\u010Db\u011B spo\u010D\u00EDv\u00E1 v monitoringu dynamiky poopera\u010Dn\u00EDho/ postradia\u010Dn\u00EDho PSA. V r\u00E1mci dispenzarice jsme \u010Dasto sv\u011Bdky PSA progrese, kter\u00E1 zpravidla jako jedin\u00FD ukazatel p\u0159edch\u00E1z\u00ED s r\u016Fzn\u011B dlouhou latenc\u00ED progresi klinick\u00E9 (tzv.%22PSA only relaps%22). \u00DAkolem urologa/onkologa je odhalit, zda se jedn\u00E1 o vzestup PSA z d\u016Fvodu lok\u00E1ln\u00ED \u010Di syst\u00E9mov\u00E9 progrese onemocn\u011Bn\u00ED. L\u00E9\u010Dba pacient\u016F s lok\u00E1ln\u00ED recidivou po opera\u010Dn\u00ED l\u00E9\u010Db\u011B je vedena ve form\u011B salvage RT s pom\u011Brn\u011B s vysokou m\u00EDrou \u00FAsp\u011B\u0161nosti a PSA odpov\u011Bd\u00ED. Salvage prostatektomie je opa\u010Dnou mo\u017Enost\u00ED pro prim\u00E1rn\u011B oz\u00E1\u0159en\u00E9 pacienty, nese v\u0161ak s sebou vy\u0161\u0161\u00ED riziko poopera\u010Dn\u00ED morbidity ne\u017E v p\u0159\u00EDpad\u011B prim\u00E1rn\u00ED operace. V n\u011Bkter\u00FDch p\u0159\u00EDpadech je indikov\u00E1na hormon\u00E1ln\u00ED l\u00E9\u010Dba (medikamentozn\u00ED \u010Di chirurgick\u00E1 kastrace \u010Di antiandrogeny)."@cs . . "Local therapy of prostate cancer means radical surgical or radiation therapy. Follow-up of prostate cancer patients comprises postoperative/postradiation PSA monitoring and its dynamics. When PSA progression is detected during follow-up, it is sometimes so called PSA only relaps without any clinical correlation. This PSA rise often precedes clinical progression with different latention. The urologist/oncologist has to differ wether PSA relaps due to local or systemic progression occurs. Prostate cryotherapy or brachyradiotherapy are another treatment options after primary RT, although predominantly more experimental. Systemic progression is predictable with 80 per cent probability if following factors are present: time to PSA relaps shorter than one year, PSA DT 4-6 months, staging pT3b or pN1 and Gleason score 8-10. In such cases hormonal treatment (medical or surgical castration or antiandrogens) is indicated."@en . "Gal\u00E9n" . . "978-80-7262-450-8" . "Praha" . . "Praha" . . . . "15110" . "failure of local therapy; prostate carcinoma"@en . "Selh\u00E1n\u00ED lok\u00E1ln\u00ED terapie karcinomu prostaty"@cs . . . "Failure of prostate cancer local therapy"@en . "2011-11-23+01:00"^^ . . . "KR\u00C1L, Milan" . "[EEE639BC39B1]" . . "228743" . . "1"^^ . "2"^^ . "P(GD303/09/H048), P(NS9940), Z(MSM6198959216)" . . "Selh\u00E1n\u00ED lok\u00E1ln\u00ED terapie karcinomu prostaty" . . "Selh\u00E1n\u00ED lok\u00E1ln\u00ED terapie karcinomu prostaty"@cs . "1"^^ . "RIV/61989592:15110/11:10225271" . . "Lok\u00E1ln\u00ED terapi\u00ED karcinomu prostaty rozum\u00EDme radik\u00E1ln\u00ED opera\u010Dn\u00ED \u010Di radia\u010Dn\u00ED l\u00E9\u010Dbu. Sledov\u00E1n\u00ED pacient\u016F po ukon\u010Den\u00E9 l\u00E9\u010Db\u011B spo\u010D\u00EDv\u00E1 v monitoringu dynamiky poopera\u010Dn\u00EDho/ postradia\u010Dn\u00EDho PSA. V r\u00E1mci dispenzarice jsme \u010Dasto sv\u011Bdky PSA progrese, kter\u00E1 zpravidla jako jedin\u00FD ukazatel p\u0159edch\u00E1z\u00ED s r\u016Fzn\u011B dlouhou latenc\u00ED progresi klinick\u00E9 (tzv.%22PSA only relaps%22). \u00DAkolem urologa/onkologa je odhalit, zda se jedn\u00E1 o vzestup PSA z d\u016Fvodu lok\u00E1ln\u00ED \u010Di syst\u00E9mov\u00E9 progrese onemocn\u011Bn\u00ED. L\u00E9\u010Dba pacient\u016F s lok\u00E1ln\u00ED recidivou po opera\u010Dn\u00ED l\u00E9\u010Db\u011B je vedena ve form\u011B salvage RT s pom\u011Brn\u011B s vysokou m\u00EDrou \u00FAsp\u011B\u0161nosti a PSA odpov\u011Bd\u00ED. Salvage prostatektomie je opa\u010Dnou mo\u017Enost\u00ED pro prim\u00E1rn\u011B oz\u00E1\u0159en\u00E9 pacienty, nese v\u0161ak s sebou vy\u0161\u0161\u00ED riziko poopera\u010Dn\u00ED morbidity ne\u017E v p\u0159\u00EDpad\u011B prim\u00E1rn\u00ED operace. V n\u011Bkter\u00FDch p\u0159\u00EDpadech je indikov\u00E1na hormon\u00E1ln\u00ED l\u00E9\u010Dba (medikamentozn\u00ED \u010Di chirurgick\u00E1 kastrace \u010Di antiandrogeny)." . . "Selh\u00E1n\u00ED lok\u00E1ln\u00ED terapie karcinomu prostaty" . "Failure of prostate cancer local therapy"@en .